Diagnosis, featured, Innovation, Memory, Prevention

When One Door Closes

What the Failure of Biogen’s Aducanumab Tells Us About Alzheimer’s — Risk Reduction is Still Our Best Weapon Today I serve as Neurotrack’s Head Writer. But three years ago, in a different professional incarnation, I had the privilege of sitting in a packed conference room with a bright, articulate representative from the pharmaceutical company Biogen […]

Read more